Veracyte is a Hold: Decipher growth is slowing, with management planning a 40% lower annual increase; consensus expects 2027 EPS to fall 19.38%. Click for more on VCYT stock.
Why Veracyte Stock Is Back Under The Microscope Veracyte (VCYT) rattled investors after resetting near term expectations for its Decipher prostate cancer test, even as quarterly revenue growth remained solid and management trimmed 2026 guidance. The latest reset around Decipher came on top of a sharp swing in sentiment, with Veracyte’s share price down 51.69% over the past week and 48.84% over the last three months, while the 1-year total shareholder return has fallen 42.06% even though the...
Veracyte (NasdaqGM:VCYT) reported new predictive data on its Decipher Prostate Genomic Classifier in very high-risk nonmetastatic prostate cancer. The findings support using Decipher to identify patients who may benefit from adding abiraterone to androgen deprivation therapy in this setting. The updated NCCN guidelines now recognize this evidence, giving the Decipher Prostate test formal guideline support in high-risk treatment decisions. The fresh predictive evidence and NCCN guideline...
Motley Fool Press Release.
Veracyte stock crashed almost 40% early Thursday after the company reset growth expectations for its prostate cancer test.
Explore why Veracyte is rated a buy: strong test demand, 15% revenue growth, rising margins, and new product expansion. Click for more on VCYT stock.
Veracyte (VCYT) is back in focus after new phase III data on its Decipher Prostate Genomic Classifier showed it can help identify which intermediate-risk prostate cancer patients benefit most from adding short-term hormone therapy. Investors have seen momentum cool in recent weeks, with Veracyte’s share price falling 4.0% on the day and 9.0% over the past week, while the 90 day share price return is down 22.6%. Yet the 1 year total shareholder return of 24.0% and 3 year total shareholder...
Veracyte (NasdaqGM:VCYT) reported new phase III data showing its Decipher Prostate Genomic Classifier can guide hormone therapy use with radiation in intermediate-risk prostate cancer. The phase III trial provided prospective evidence that Decipher can help identify which patients are more likely to benefit from adding hormone therapy to radiation treatment. Findings suggest Decipher may extend its role from prognosis to predicting treatment benefit, potentially influencing how clinicians...
Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Veracyte (VCYT) is adding an adjacent product to its bladder franchise following its acquisition of
Veracyte (VCYT) said late Monday it has acquired Convergent Genomics for $150 million in upfront cas
Detailed price information for Veracyte Inc (VCYT-Q) from The Globe and Mail including charting and trades.
Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
Detailed price information for Veracyte Inc (VCYT-Q) from The Globe and Mail including charting and trades.
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
This is the newest page. Registered accounts read further back.